الرئيسية › ابيضاض الدم النقوي الحاد › بنسلفانيا › Philadelphia
التجارب السريرية لـ ابيضاض الدم النقوي الحاد في Philadelphia، PA
34 دراسات لـ ابيضاض الدم النقوي الحاد تبحث عن مشاركين في مواقع داخل وحول Philadelphia (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Thomas Jefferson University Hospital, Philadelphia
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
جارٍ التسجيلالمرحلة 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 1
- Children's Hospital of Philadelphia, Philadelphia
Assessment of Geriatric Evaluations Impact on New AML Guidance
جارٍ التسجيلدراسة رصدية
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · على بُعد 22 ميل
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
جارٍ التسجيلدراسة رصدية
- Children's Hospital of Philadelphia, Philadelphia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
جارٍ التسجيلالمرحلة 3
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Thomas Jefferson University Hospital, Philadelphia
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
جارٍ التسجيلالمرحلة 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
جارٍ التسجيلالمرحلة 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
جارٍ التسجيلالمرحلة 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · على بُعد 25 ميل
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
جارٍ التسجيلالمرحلة 1/2
- University of Pennsylvania, Philadelphia
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
جارٍ التسجيلالمرحلة 1
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 3
- Children's Hospital of Philadelphia, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · على بُعد 25 ميل
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
جارٍ التسجيلالمرحلة 1/2
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · على بُعد 25 ميل
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
جارٍ التسجيلالمرحلة 3
- Children's Hospital of Philadelphia, Philadelphia
- Nemours Alfred I. Dupont Hospital for Children, Wilmington · على بُعد 25 ميل
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
جارٍ التسجيلالمرحلة 3
- University of Pennsylvania, Philadelphia
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
جارٍ التسجيلالمرحلة 2/3
- University of Pennsylvania, Philadelphia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 1
- Children's Hospital of Philadelphia, Philadelphia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
جارٍ التسجيلالمرحلة 2
- Penn Medicine Abramson Cancer Center, Philadelphia
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
جارٍ التسجيلالمرحلة 1
- University of Pennsylvania, Philadelphia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
جارٍ التسجيل
- Children's Hospital of Philadelphia, Philadelphia
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 1
- Children's Hospital of Philadelphia, Philadelphia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
جارٍ التسجيلدراسة رصدية
- Children's Hospital of Philadelphia, Philadelphia
- Nemours - Alfred I. duPont Hospital for Children, Brandywine · على بُعد 21 ميل
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
جارٍ التسجيلالمرحلة 1/2
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
جارٍ التسجيلالمرحلة 1
- University of Pennsylvania, Philadelphia
Massage Impact on Sleep in Pediatric Oncology
جارٍ التسجيل
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
جارٍ التسجيلالمرحلة 1/2
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Phase IB/II of CPX-351 for Relapse Prevention in AML
جارٍ التسجيلالمرحلة 1/2
- University of Pennsylvania, Philadelphia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
جارٍ التسجيلالمرحلة 1
- Thomas Jefferson University Hospital, Philadelphia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
جارٍ التسجيلالمرحلة 1
- Hospital of the University of Pennsylvania, Philadelphia
Tazemetostat and Palbociclib With CPX-351for R/R AML
جارٍ التسجيلالمرحلة 1
- Thomas Jefferson University Hospital, Philadelphia
Home Blood Transfusions
جارٍ التسجيل
- Thomas Jefferson University Hospital, Philadelphia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- University of Pennsylvania, Philadelphia
تجارب ابيضاض الدم النقوي الحاد في مدن أخرى
- Houston, TX85 دراسات
- New York City, NY51 دراسات
- Boston, MA44 دراسات
- Seattle, WA41 دراسات
- Baldwin Park, CA40 دراسات
- Columbus, OH35 دراسات
- Durham, NC33 دراسات
- Atlanta, GA31 دراسات
- Tampa, FL29 دراسات
- Chicago, IL26 دراسات
- Portland, OR25 دراسات
- Washington, DC24 دراسات
دراسات أخرى في Philadelphia
- السرطان (جميع الأنواع)59 دراسات
- سرطان الثدي56 دراسات
- سرطان الرئة غير صغير الخلايا51 دراسات
- السرطان النقيلي46 دراسات
- سرطان البروستاتا44 دراسات
- سرطان القولون والمستقيم44 دراسات
- سرطان المبيض44 دراسات
- سرطان الرئة36 دراسات
- قصور القلب31 دراسات
- سرطان بطانة الرحم28 دراسات
- الاكتئاب26 دراسات
- سرطان البنكرياس26 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.